Loading...
Loading...
OBIO| Name | Value |
|---|---|
| Revenues | 0.6M |
| Cost of Revenue | 0.1M |
| Gross Profit | 0.5M |
| Operating Expense | 14.9M |
| Operating I/L | -14.4M |
| Other Income/Expense | 1.0M |
| Interest Income | 1.0M |
| Pretax | -13.5M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -13.5M |
Orchestra BioMed Holdings, Inc. is a biomedical innovation company specializing in developing advanced medical products. Its flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for hypertension treatment and Virtue Sirolimus AngioInfusion Balloon (SAB) for atherosclerotic artery disease. Additionally, the company offers FreeHold retractors, minimally invasive surgical device solutions. Orchestra BioMed has strategic collaborations with Medtronic and Terumo Corporation for the development and commercialization of its products. These partnerships enable the company to generate revenue through the sale and licensing of its innovative medical technologies.
